Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelial–mesenchymal transition

Xie, Min; Nie, Fengqi; Sun, Ming; Xia, Ruixiang; Zhou, Peng; De, Wei; Li, Xianghua

doi:10.1186/s12967-015-0595-9

Cited by 92 publications

(87 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xie et al 61 found that the expression of SPRY4-IT1 was significantly downregulated in GC tissues and cell lines compared with normal control. They also found that downregulation of SPRY4-IT1 was significantly correlated with GC tumor size, advanced pathological stage, deeper depth of invasion, and lymphatic metastasis.…”

Section: Gcmentioning

confidence: 99%

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

Chen

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Long non-coding RNAs are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that long non-coding RNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. Among numerous long non-coding RNAs, we focus on Sprouty4-Intron 1 (SPRY4-IT1), a well-known long non-coding RNA that is overexpressed in various kinds of tumor tissues and cell lines. Accumulating evidences show that SPRY4-IT1 was dysregulated in various cancers, including melanoma, breast cancer, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and hepatocellular carcinoma, and amplification of SPRY4-IT1 was associated with different clinicopathological features of cancer patients. Importantly, SPRY4-IT1 exerts important roles in tumor progression and metastasis. However, detailed molecular mechanisms of SPRY4-IT1 in cancer progression and metastasis were poorly understood. In this review, we have focused on the characteristics of SPRY4-IT1 and illustrated the biological function and mechanism of SPRY4-IT1 in cancer development.

show abstract

Section: Gcmentioning

confidence: 99%

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

Chen

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

show abstract

“…For instance, a lncRNA named SPRY4 intronic transcript 1 (SPRY4-IT1) was reported to be overexpressed in melanoma, renal cell carcinoma, esophageal squamous cell carcinoma, breast cancer, bladder cancer and glioma, and associated with poor prognosis and promotion of tumor growth (24)(25)(26)(27)(28)(29). Certain studies also demonstrated that SPRY4-IT1 expression was decreased in non-small-cell lung cancer and gastric cancer, and acted with significant antitumor function in these two types of cancer (30,31). Similarly, HOTTIP may exhibit a tissue-specific expression pattern and serve a different function in different types of cancer, as with SPRY4-IT.…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA HOXA transcript at the distal tip as a biomarker for gastric cancer

Yang

Yan

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract.A long non-coding RNA named HOXA transcript at the distal tip (HOTTIP) has been reported to be significantly increased in several cancers, including hepatocellular cancer, pancreatic cancer and lung cancer. However, the clinical value of HOTTIP expression in gastric cancer remains unknown. The present study aimed to investigate HOTTIP expression levels in gastric cancer and to elucidate its clinical significance. Reverse transcription polymerase chain reaction was used to assess the expression level of HOTTIP in gastric cancer cell lines and tissues. In a cohort of 94 patients with gastric cancer, HOTTIP expression was significantly lower in cancer tissues compared with the normal adjacent tissues. In addition, receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of HOTTIP in gastric cancer, and the area under the ROC curve was 0.767. In conclusion, the results of the present study indicated that HOTTIP may be a predictive biomarker for gastric cancer.

show abstract

“…Its down-regulation in cancer tissue seems to be based on promoter methylation. Target validation experiments in SGC 7901, BGC 823 and MKN 45 gastric cancer cells point to its role in inhibition of proliferation, colony formation, cell migration and invasion and its capacity to up-regulate cyclin D1, MMP2, MMP9 and E-cadherin and to down-regulate vimentin (158,159). Ectopic expression of SPRY4-IT in BGC 823 cells reduced the number of metastatic nodules after teil vein injection (158).…”

Section: Metastasis-related Lncrnas: Category IIImentioning

confidence: 99%

“…Tail vein injection experiments of these cells reveal promotion of lung metastases in comparison to control SGC 7901 cells (157). SPRY4-IT1 (SPRY4 intronic transcript 1) is derived from an intron of the SPRY gene and its decreased expression in gastric cancer correlates with overall survival (OS) and disease-free survival (DFS) (158,159). Its down-regulation in cancer tissue seems to be based on promoter methylation.…”

Section: Metastasis-related Lncrnas: Category IIImentioning

confidence: 99%

Long Non-coding RNAs and their Role in Metastasis

Weidle

Birzele

Kollmorgen

et al. 2017

CGP

168

124

View full text Add to dashboard Cite

Abstract.Metastasis is the major cause of death in patients with cancer. It is mediated by a multi-step process referred to as the metastatic cascade (1, 2). Initial steps include local invasion and migration, angiogenesis, epithelialmesenchymal transition (EMT) and intravasation. Tumor cells enter the circulation as single cells or circulating tumor cell clusters, are coated by platelets to escape an immune response and subsequently arrest in capillaries in distant organs as a prerequisite for extravasation. Colonization starts by homing of tumor cells in supporting niches of the organ parenchyma, followed by a latency phase which can last from several months to decades. A prerequiste for overt outgrowth of micrometastases is their adaptation to the local microenvironment and acquisition of colonisation-promoting traits (3-6). The pattern of colonized distant organs depends on the tumor type and can range from predominant spread to one organ and colonization of different types of organs sequentially or simultaneously (7). Several genes and their products have been identified to mediate crucial steps of the metastatic process such as metastasis initiation and progression, as well as organ-specific functions of metastasis (virulence) (8, 9). These gene products include proteases, chemokines, cytokines and their receptors, angiogenic factors, intracellular and transmembrane kinases, adhesion molecules, components of the extracellular matrix (ECM), GPI-linked receptors and carbohydrate metabolism-related enzymes (8, 9). More recently, an important impact of RNA-related molecules for metastasis has emerged. MicroRNAs (miRs) and other types of RNA modulate metastasis via regulatory networks (10,11). In this review we focus on the role of long non-coding RNAs (lncRNA) as promoters or inhibitors of metastasis in different tumor entities since there is an urgent need to define new targets for therapeutic intervention. With the exception of denosumab for treatment of bone metastases, all other agents evaluated in clinical studies for treatment of metastatic disease gave rise to mixed or disappointing results (6).

show abstract

Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelial–mesenchymal transition

Cited by 92 publications

References 32 publications

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

Long non-coding RNA HOXA transcript at the distal tip as a biomarker for gastric cancer

Long Non-coding RNAs and their Role in Metastasis

Contact Info

Product

Resources

About